SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1365)12/20/2004 1:48:25 PM
From: rjk01  Respond to of 1386
 
The way I read the CC, Aviv own words were that they are done with this one. They had to look at all poss. before making that statement. I have to conclude that we are "over and done" on this one.



To: NeuroInvestment who wrote (1365)12/20/2004 2:17:33 PM
From: Clarksterh  Read Replies (2) | Respond to of 1386
 
Thanks Neuro - 1) The dex used in this trial was not from the new manufacturing plant, and had been passed as bioequivalent to what was used previously.

I guess my follow-on question is: what is bioequivalent and how is it measured? If it is only a measure of HU-211 then ... . Not really expecting an answer at this point. Really looking forward to seeing the published data - especially the ICP data.

Clark


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News